Literature DB >> 10462758

Metalloporphyrin class of therapeutic catalytic antioxidants.

M Patel1, B J Day.   

Abstract

Metalloporphyrins have emerged as a novel class of catalytic antioxidants that scavenge a wide range of reactive oxygen species (ROS) such as superoxide, peroxide, peroxynitrite and lipid peroxyl radicals. Factors such as the type of metal centre, redox potential and electrostatic charge of the compounds are recognized as important determinants of their antioxidant activity and potency. These concepts have guided the development of metalloporphyrins with specific activities greater than those of the native superoxide dismutases. Several compounds in this class have been shown to be efficacious in a variety of in vitro and in vivo oxidative stress models of human diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462758     DOI: 10.1016/s0165-6147(99)01336-x

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  55 in total

1.  Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production.

Authors:  C M Luetjens; N T Bui; B Sengpiel; G Münstermann; M Poppe; A J Krohn; E Bauerbach; J Krieglstein; J H Prehn
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

2.  Differential regulation of wheat quinone reductases in response to powdery mildew infection.

Authors:  David L Greenshields; Guosheng Liu; Gopalan Selvaraj; Yangdou Wei
Journal:  Planta       Date:  2005-08-04       Impact factor: 4.116

Review 3.  Catalytic antioxidants to treat amyotropic lateral sclerosis.

Authors:  John P Crow
Journal:  Expert Opin Investig Drugs       Date:  2006-11       Impact factor: 6.206

4.  Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease.

Authors:  Li-Ping Liang; Jie Huang; Ruth Fulton; Jennifer N Pearson-Smith; Brian J Day; Manisha Patel
Journal:  Toxicol Appl Pharmacol       Date:  2017-04-08       Impact factor: 4.219

Review 5.  [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].

Authors:  K Kollewe; R Dengler; S Petri
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

6.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

Authors:  M Aslan; T M Ryan; B Adler; T M Townes; D A Parks; J A Thompson; A Tousson; M T Gladwin; R P Patel; M M Tarpey; I Batinic-Haberle; C R White; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

7.  Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria.

Authors:  Tongzu Liu; Bethany Hannafon; Lance Gill; William Kelly; Doris Benbrook
Journal:  Mol Cancer Ther       Date:  2007-06       Impact factor: 6.261

Review 8.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

9.  Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome.

Authors:  Leah R Villegas; Dylan Kluck; Carlie Field; Rebecca E Oberley-Deegan; Crystal Woods; Michael E Yeager; Karim C El Kasmi; Rashmin C Savani; Russell P Bowler; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2013-02-05       Impact factor: 8.401

10.  Control of Bcl-2 expression by reactive oxygen species.

Authors:  David A Hildeman; Thomas Mitchell; Bruce Aronow; Sara Wojciechowski; John Kappler; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.